Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 143

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 143
---
, including, for example, the
type of investment, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is
based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment
and the investments are categorized as Level 3.

The carrying
amounts of cash and cash equivalents, other current assets, accounts payables, other account payables and convertible notes approximate
their fair value due to the short-term maturities of such instruments.

<div align='center'>F-38</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (Cont.)

| n. | Legal and other contingencies: |

The Company
accounts for its contingent liabilities in accordance with ASC 450 “Contingencies”. A provision is recorded when it is both
probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions
are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other
information and events pertaining to a particular matter. As of December 31, 2023, and 2022, the Company is not a party to any litigation
that could have a material adverse effect on the Company’s business, financial position, results of operations or cash flows.

| o. | Basic and diluted loss per share: |

Basic loss
per share is computed by dividing the loss for the period applicable to Ordinary Shareholders by the weighted average number of shares
of common stock. Par value $0.001 per share (the “Common Stock”) outstanding during the period.

In computing
diluted loss per share, basic loss per share is adjusted to reflect the potential dilution that could occur upon the exercise of warrants
using the “treasury stock method”, if the effect of each of such financial instruments is dilutive.

All outstanding
share options and warrants for the years ended December 31, 2023, and 2022 have been excluded from the calculation of the diluted net
loss per share, because all such securities are anti-dilutive for all periods presented. The potential shares of ordinary shares that
were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because
including them would have